1. Acute asthma intervention: Insights from the STAY study
Paul M. O'Byrne, MB, FRCP(C) 
Journal of Allergy and Clinical Immunology 
Volume 119, Issue 6, Pages (June 2007)
DOI: /j.jaci
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
All severe asthma exacerbations requiring medical intervention in the STAY study. Each exacerbation is represented by a line, and the length of the line represents the duration of the exacerbation. Patients receiving budesonide (Bud) 800 μg/d with terbutaline as reliever are in the upper panel; patients receiving budesonide/formoterol (Form) 200/6 μg/d with terbutaline as reliever are in the middle panel; and patients receiving budesonide/formoterol 200/6 μg/d with budesonide/formoterol as reliever are in the lower panel. Budesonide/formoterol as maintenance and reliever significantly reduced the number of severe exacerbations compared with the other 2 groups.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Number of severe exacerbations in the STAY study during 1 year of treatment with budesonide (Bud) 800 μg/d with terbutaline as rescue inhaler, or budesonide/formoterol 200/6 μg/d with terbutaline as rescue inhaler, or budesonide/formoterol 200/6 μg/d with budesonide/formoterol as rescue inhaler (left panel). Also shown are the number of exacerbations defined by the fall in PEF criterion (>30% from baseline for 2 consecutive days), or by the number of oral corticosteroid courses decided by the managing physician, or by a hospitalization of emergency department (ED) visit. Budesonide/formoterol used both as maintenance and reliever significantly reduced the number of exacerbations in all categories. Data from reference 13.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
All severe asthma exacerbations requiring medical intervention in the children (age 4-11 years) in the STAY study. Each exacerbation is represented by a line, and the length of the line represents the duration of the exacerbation. Patients receiving budesonide (Bud) 400 μg/d with terbutaline as reliever are in the upper panel; patients receiving budesonide/formoterol (Form) 100/6 μg/d with terbutaline as reliever are in the middle panel; and patients receiving budesonide/formoterol 100/6 μg/d with budesonide/formoterol as reliever are in the lower panel. Budesonide/formoterol as maintenance and reliever significantly reduced the number of severe exacerbations compared with the other 2 groups.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions